Alector, Inc. (ALEC): Shareholders' Equity
$30.65M
As of 2025-12-31
-$9.97M
As of 2026-06-30
-47.7%
3-year compound annual growth
-35.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.65M | -75.8% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $126.80M | -5.5% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $134.16M | -37.4% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $214.44M | -28.7% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $300.72M | +12.4% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $267.53M | +37.4% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $194.74M | n/m | 2022-02-24, Balance as of period end |
| 2018-12-31 | -$97.40M | n/m | 2021-02-25, Balance as of period end |
| 2017-12-31 | -$52.03M | n/a | 2020-03-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Alector, Inc. (ALEC) | 2025-12-31 | $30.65M | -75.8% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $284.34M | +39.3% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $158.60M | -32.5% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $38.88M | n/m |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $567.06M | -27.1% |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$207.78M | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $43.35M | -43.7% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $92.25M | +63.6% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $186.29M | +741.1% |
Compare ALEC, LENZ, MGX, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗